Kevin McNamara compensation by year
CHEMED Summary Compensation Table · all 7 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $1,149,908 | $1,217,317 | $1,305,992 | $1,490,333 | $1,604,000 | $1,738,117 | $1,858,792 |
| Bonus | — | $0 | $0 | — | $0 | $0 | $0 |
| Stock awards | $1,676,824 | $1,702,215 | $2,168,162 | $2,135,216 | $2,511,638 | $2,375,477 | $2,883,553 |
| Option awards | $2,014,815 | $3,411,139 | $4,021,813 | $3,744,820 | $4,200,094 | $4,619,937 | $5,036,021 |
| Non-equity incentive | $2,705,855 | $2,409,428 | $3,065,892 | $2,664,155 | $2,923,712 | $2,628,448 | $1,486,976 |
| Pension and deferred compensation | $22,299 | $48,969 | $54,566 | $66,356 | $73,012 | $81,084 | $88,175 |
| All other | $1,208,936 | $1,230,782 | $1,341,998 | $1,508,153 | $1,312,650 | $1,326,501 | $1,551,203 |
| Total | $8,778,637 | $10,019,850 | $11,958,423 | $11,609,033 | $12,625,106 | $12,769,564 | $12,904,720 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CHEMED CORP DEF 14A filed April 9, 2026, accession 0001562762-26-000052, and prior-year filings.
How this page was built: the CHEMED CORP filed document, accession 0001562762-26-000052. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2026.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 9, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-01 | Sale | — | 2,000 | $421.13 | 90,219 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CHEMED’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kevin McNamara · this page | President and CEO | $12,904,720 |
| Nicholas Westfall | Former Executive Vice President | $4,294,862 |
| Michael Witzeman | Executive Vice President, CFO and Controller | $3,714,742 |
| Spencer Lee | Executive Vice President | $3,208,764 |
| Joel Wherley | Vitas President and Chief Executive Officer | $3,049,989 |
| Brian Judkins | Vice President, Secretary and Chief Legal Officer | $2,658,997 |
Board service
CHEMED board · FY2021–FY2025How this board is paid
Company policy: CHEMED pays directors a $80,000 cash retainer and $160,394 in Stock. As stated in CHEMED's FY2025 proxy.
The full CHEMED compensation record
free company briefThis page is one person within CHEMED's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CHEMED proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CHEMED's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CHEMED's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.